Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc.
47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 517
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 984.09k | 461.21k | 1976 |
| Ms. Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 733.94k | N/A | 1963 |
| Mr. David M. Clark | Chief People Officer | 701.39k | N/A | 1975 |
| Dr. Jeffrey P. Castelli | Chief Development Officer | 709.64k | 88.61k | 1972 |
| Mr. Simon Nicolas Reade Harford | Chief Financial Officer | N/A | N/A | 1960 |
| Ms. Samantha Prout | Chief Accounting Officer & Controller | N/A | N/A | 1978 |
| Dr. Jill Weimer Ph.D. | Chief Science Officer | N/A | N/A | N/A |
| Andrew Faughnan | Senior Director of Investor Relations | N/A | N/A | N/A |
| Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | N/A | N/A | N/A |
| Ms. Diana Moore | Head of Global Corporate Communications | N/A | N/A | N/A |
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Corporate governance
Amicus Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 7; Compensation: 5.
